| Date | Title | Description |
| 16.09.2026 | Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks | Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW)
Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment approved for the prevention of migraine attacks in adults and launched in over 30 countrie... |
| 24.08.2026 | European Commission grants orphan designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin | European Commission grants orphan designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
Mon, Aug 24, 2026 09:00 CET Report this content The European Commission has gra... |
| 19.08.2026 | Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026 | VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ --
Key highlights
Lundbeck's total revenue grew by +16% CER[1] (+11% DKK) to DKK 13,588 million in the first six months of 2026, with the U.S. and Europe delivering double-digit growth. The perform... |
| 19.08.2026 | Strong growth from Vyepti[®] and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026 | Strong growth from Vyepti[®] and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
Wed, Aug 19, 2026 07:00 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +16% CER[1... |
| 19.08.2026 | Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S | Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S
Wed, Aug 19, 2026 07:06 CET Report this content
H. Lundbeck A/S (“Lundbeck”) hereby informs that Lundbeckfond Invest A/S (“Lundbeckfond Invest”), a fu... |
| 11.08.2026 | Moberg Pharma strengthens organization ahead of European launch | Moberg Pharma strengthens organization ahead of European launch
Tue, Aug 11, 2026 08:00 CET Report this content
STOCKHOLM, August 11, 2026. Moberg Pharma AB (OMX: MOB) announces changes to its management team and strengthens the organizatio... |
| 28.07.2026 | «Герофарм» не смог оспорить патент Lundbeck на вортиоксетин | «Герофарм» не смог оспорить патент Lundbeck на вортиоксетин
Роспатент отказал российской компании «Герофарм» в удовлетворении возражения против действия на территории России евразийского патента датской Lundbeck на вортиоксетин — действующе... |
| 23.07.2026 | Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy | Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
Thu, Jul 23, 2026 09:00 CET Report this content The U.S. FDA has granted Fast Track designation to Lu AH69593, an oral ... |
| 20.07.2026 | Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs) | DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1
Broadest pivotal trial to date, enrolling patients... |
| 20.07.2026 | Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs) | Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
Mon, Jul 20, 2026 09:00 CET Report this content DEEp OCEAN is a global trial designed to evaluate the i... |
| 24.06.2026 | Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026 | Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart
Eptinezumab data ... |
| 24.06.2026 | Tarek Samad appointed EVP, Head of Research & Development at Lundbeck | VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Te... |
| 24.06.2026 | Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026 | Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
Wed, Jun 24, 2026 09:00 CET Report this content
Five migraine presentations will showcase Lundbeck’s current and future approaches to migraine pr... |
| 24.06.2026 | Tarek Samad appointed EVP, Head of Research & Development at Lundbeck | Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
Wed, Jun 24, 2026 11:30 CET Report this content
Valby, Denmark, 24 June, 2026 – H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executi... |
| 19.06.2026 | Vedana Therapeutics Raises $46 Million To Advance Next-Generation Migraine Therapies | Vedana Therapeutics emerged from stealth with $46 million in Series A funding to advance next-generation therapies for migraine prevention.
The funding round was co-led by Westlake BioPartners and Canaan Partners, with participation from Da... |
| 15.06.2026 | Cushing’s Disease Drug Targets ACTH Directly, Normalizes Cortisol in 87.5% of Patients | By John Bright
Published: Jun 15 2026, 10:08 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 14.06.2026 | Lundbeck presents new Phase II asedebart data in Cushing’s disease at ENDO 2026 | Lundbeck presents new Phase II asedebart data in Cushing’s disease at ENDO 2026
Sun, Jun 14, 2026 21:45 CET Report this content Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (A... |
| 10.06.2026 | Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026 | Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
Wed, Jun 10, 2026 08:00 CET Report this content Upcoming presentations at ENDO 2026 highlight Lundbeck’s Focused Innovator strategy and continu... |
| 04.06.2026 | Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress | Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
Thu, Jun 04, 2026 22:00 CET Report this content The intravenous part of the Phase IIb clinical dose-finding tri... |
| 03.06.2026 | Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments | Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments
Wed, Jun 03, 2026 14:00 CET Report this content
Collaboration’s initial focus will focus on two antibody programs targeting CNS diseases
VALBY, Denmark & A... |
| 01.06.2026 | South Korea Approves Vyepti for Migraine Prevention: A New Era in Neurological Care | Lundbeck announces Vyepti (eptinezumab) approval in South Korea for adult migraine prevention. This intravenous anti-CGRP monoclonal antibody offers a critical new treatment. Migraine affects 11% of the Korean population, a debilitating neu... |
| 26.05.2026 | Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine | Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS)
Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adults
Authorization supported by the Ph... |
| 26.05.2026 | Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine | Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
Tue, May 26, 2026 08:00 CET Report this content Approval granted by South Korea’s Ministry of Food and Drug Safety (... |
| 18.05.2026 | Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease | Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease
Mon, May 18, 2026 10:03 CET Report this content Congenital adrenal hyperplasia (CAH) an... |
| 18.05.2026 | Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease | Congenital adrenal hyperplasia (CAH) and Cushing's disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain1,2
Current treatments are limited by suboptimal disease control and treatmen... |
| 12.05.2026 | Lundbeck raises financial guidance for 2026 | Lundbeck raises financial guidance for 2026
Tue, May 12, 2026 11:15 CET Report this content
H. Lundbeck A/S (Lundbeck) raises financial guidance for the full-year revenue and adjusted EBITDA growth at constant exchange rates (CER).
Lundbeck... |
| 12.05.2026 | Strong start to 2026: +21% CER revenue growth (+13% CER underlying) | Strong start to 2026: +21% CER revenue growth (+13% CER underlying)
Tue, May 12, 2026 11:22 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +21% CER[1] (+14% DKK) to DKK 7,125 million in the first quarter of 2026, wi... |
| 20.04.2026 | Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab) | • The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure
VALBY, Denma... |
| 19.04.2026 | Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab) | Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
Sun, Apr 19, 2026 15:00 CET Report this content The one-year INFUSE study observed patient-re... |
| 13.04.2026 | Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting | Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
Mon, Apr 13, 2026 09:00 CET Report this content
Seven abstracts represent data across migraine, childhood-onset epilepsy and multiple system atrophy... |
| 22.03.2026 | Europe's Corporate Evolution: AGM Insights and Sustainability Imperatives | European firms Lundbeck and Posti Group recently unveiled key corporate updates. Lundbeck's AGM approved dividends, new board members, and a share repurchase. Posti released its 2025 Annual Report, highlighting financial results and robust ... |
| 18.03.2026 | Lundbeck held its Annual General Meeting on 18 March 2026 at the company’s registered office | Lundbeck held its Annual General Meeting on 18 March 2026 at the company’s registered office
Wed, Mar 18, 2026 13:00 CET Report this content
H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted an... |
| 16.03.2026 | Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026 | Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026
Mon, Mar 16, 2026 09:00 CET Report this content Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be prese... |
| 10.03.2026 | Lundbeck appoints Chief AI Officer | Lundbeck appoints Chief AI Officer
Tue, Mar 10, 2026 09:00 CET Report this content
Valby, Denmark, 10 March 2026 – H. Lundbeck A/S (Lundbeck) today announced the appointment of Markus Kede as Senior Vice President, Chief AI Officer. He will... |
| 09.03.2026 | Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial | Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial
Mon, Mar 09, 2026 10:33 CET Report this content MASCOT is a first-of-its-kind, Phase 3 trial supporting the development of amlenetug, an investigational th... |
| 03.03.2026 | BioInnovation Institute backs five startups with €1.3M in follow-on funding | BioInnovation Institute (BII), an initiative of the Novo Nordisk Foundation, has awarded an additional €1.3 million in follow-on funding to five portfolio startups, bringing total support per company to up to €1.8 million. The funding is in... |
| 26.02.2026 | Slate Medicines Secures $130M to Advance Migraine Prevention | Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach... |
| 24.02.2026 | Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine Therapies | Slate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a... |
| 18.02.2026 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Wed, Feb 18, 2026 09:32 CET Report this content
1. Details of the person discharging managerial responsibilities / person clo... |
| 17.02.2026 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 17, 2026 10:00 CET Report this content NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00... |
| 12.02.2026 | Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention | Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention
Thu, Feb 12, 2026 16:39 CET Report this content The intravenous (IV) part of the phase IIb dose-finding PROCEED trial... |
| 06.02.2026 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Fri, Feb 06, 2026 11:39 CET Report this content
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by ... |
| 04.02.2026 | Lundbeck Annual Report 2025 | Lundbeck Annual Report 2025
Wed, Feb 04, 2026 07:50 CET Report this content
Annual report 2025 in XHTML format submitted to the Danish Financial Supervisory Authority (The Officially Appointed Mechanisms)
H. Lundbeck A/S
Ottiliavej 9, 2500 ... |
| 04.02.2026 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Wed, Feb 04, 2026 19:13 CET Report this content
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by ... |
| 04.02.2026 | Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026 | Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026
Wed, Feb 04, 2026 07:30 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +13% CER[1] (+12%... |
| 30.01.2026 | Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference | Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
Fri, Jan 30, 2026 15:00 CET Report this content New six-month r... |
| 26.01.2026 | €76 million Footprint Fund I to support 30 early-stage climate and DeepTech companies across Northern Europe | “With Footprint Fund I, we are doubling down on our mission to accelerate what is necessary,” said Anna Søndergaard, co-founding Partner and CEO at The Footprint Firm. “The future worth building will not arrive by chance, it must be venture... |
| 31.12.2025 | M&A deals won’t break 2024 record | Last year’s megadeals meant 2025 had a tough act to follow. Gerry Byrne finds that while transactions are at a similar level to 2024, the value of M&A activity in the last 12 months is unlikely to reach the same peak
Despite the number ... |
| 08.12.2025 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Mon, Dec 08, 2025 08:22 CET Report this content
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by ... |
| 06.12.2025 | Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting | Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Sat, Dec 06, 2025 18:00 CET Report this content New long-term data presented at AES 202... |
| 02.12.2025 | Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting | Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Tue, Dec 02, 2025 08:00 CET Report this content New data to be presented at the 20... |
| 26.11.2025 | ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RU... | ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”)
Wed, Nov 26, 2025 17:23 CET Report... |
| 14.11.2025 | Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine | Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), marking a significant step forward towards expanding access to the novel preventive migraine treatment for pat... |
| 14.11.2025 | Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine | Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
Fri, Nov 14, 2025 08:55 CET Report this content Lundbeck's new drug application (NDA) for Vyepti® (eptine... |
| 14.11.2025 | ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND MAR ARTICLE 17 (INSIDE INFORMATION) | ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND MAR ARTICLE 17 (INSIDE INFORMATION)
Fri, Nov 14, 2025 12:44 CET Report this content
NOT FOR RELEASE, PUBL... |
| 13.11.2025 | Nasdaq closes higher, snapping three-day losing streak as tech stocks recover some ground | The Nasdaq Composite rebounded on Friday as investors bought up shares of key technology stocks a day after the group led Wall Street to its worst day in more than a month.
The tech-heavy Nasdaq gained 0.13% to finish at 22,900.59, snapping... |
| 12.11.2025 | Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments | VALBY, Denmark, Nov. 12, 2025 /PRNewswire/ -- Key highlights
Lundbeck's total revenue grew by +14% CER[1] (+13% DKK) to DKK 18,537 million in the first nine months of 2025. Growth in the U.S. and Europe was the driver of this strong perform... |
| 11.11.2025 | Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments | Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments
Tue, Nov 11, 2025 15:34 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +14% CER[1... |
| 11.11.2025 | Lundbeck raises financial guidance for 2025 | Lundbeck raises financial guidance for 2025
Tue, Nov 11, 2025 15:21 CET Report this content
H. Lundbeck A/S (Lundbeck) increases its full-year 2025 financial guidance for both revenue and adjusted EBITDA growth at constant exchange rates (C... |
| 27.10.2025 | Lundbeck and OpenAI join forces to unlock innovation and boost productivity | Lundbeck and OpenAI join forces to unlock innovation and boost productivity
Mon, Oct 27, 2025 09:00 CET Report this content
Valby, Denmark, 27 October 2025 – H. Lundbeck A/S (Lundbeck) today announced a strategic collaboration with OpenAI t... |
| 20.10.2025 | Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions | Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions
Mon, Oct 20, 2025 09:00 CET Report this content
Valby, Denmark, 20 October 2025 – H. Lundbeck A/S (Lundbeck) ... |
| 13.10.2025 | Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies | Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies
Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental... |
| 13.10.2025 | Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies | Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies
Mon, Oct 13, 2025 08:00 CET Report this content Accelerated pathway underscores urgent need for innovative sol... |
| 02.10.2025 | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025 | Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 20251-3
MSA is a rar... |
| 02.10.2025 | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025 | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025
Thu, Oct 02, 2025 09:00 CET Report this content Details of the Phase 3 M... |
| 20.09.2025 | Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD | Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD
Sat, Sep 20, 2025 08:00 CET Report this content
Valby, Denmark, 20 ... |
| 11.09.2025 | Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine | Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
Thu, Sep 11, 2025 08:00 CET Report this content Lundbeck demonstrates leadership ... |
| 11.09.2025 | Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine | Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on epti... |
| 09.09.2025 | Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025 | Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025
Tue, Sep 09, 2025 14:30 CET Report this content Three new regional partnerships will secure continuity of today’s commercial activities... |
| 25.08.2025 | Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy | Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
Mon, Aug 25, 2025 09:00 CET Report this content The full results of the open label extension... |
| 25.08.2025 | Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy | The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at th... |
| 13.08.2025 | Guidance raised based on solid H1 results and continued strong expectations for the full year 2025 | Guidance raised based on solid H1 results and continued strong expectations for the full year 2025
Wed, Aug 13, 2025 18:40 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +14% CER[1] (+14% DKK) to DKK 12,258 million ... |
| 13.08.2025 | Lundbeck raises financial guidance for 2025 | Lundbeck raises financial guidance for 2025
Wed, Aug 13, 2025 18:34 CET Report this content
H. Lundbeck A/S (Lundbeck) raises the financial guidance for the full-year revenue and adjusted EBITDA growth at constant exchange rates (CER).
Lund... |
| 06.08.2025 | Named 'Great Place to Work,' Moon Rabbit Reports Record Growth, New Clients, Industry Accolades | Moon Rabbit
Independent agency forges key industry partnerships, hires 28 new employees to fuel expansion
NEW YORK, Aug. 6, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and health... |
| 22.07.2025 | Hacking the Immune System for Brain Drug Delivery: Interview with Adaptin Co-Founder and CEO Michael Roberts | Share
Share
Share
Share
Email
The blood-brain barrier (BBB) has long stood as one of the greatest challenges in medicine, thwarting efforts to deliver therapeutics to the brain and leaving many neurological conditions with few effective tre... |
| 19.07.2025 | Otsuka, Lundbeck’s PTSD Drug Fails to Win US FDA Panel Support | - |
| 18.07.2025 | Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD) | Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD)
Fri, Jul 18, 2025 23:24 CET Report this content
Valby, Denmark, 18 July 202... |
| 24.06.2025 | Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia | Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia
Tue, Jun 24, 2025 08:00 CET Report this content
Congenital adrenal hyperplasia (CAH) is a rare autos... |
| 23.06.2025 | Eptinezumab: A New Dawn for Chronic Migraine Sufferers | Chronic migraine is a relentless storm, battering the lives of millions. For those caught in its grip, the search for relief can feel like navigating a maze with no exit. However, recent breakthroughs in migraine treatment, particularly wit... |
| 21.06.2025 | New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine | New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
Sat, Jun 21, 2025 13:20 CET Report this content The full results of the phase III registrational SUNRISE trial were presented... |
| 21.06.2025 | New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine | New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
Sat, Jun 21, 2025 13:25 CET Report this content The full results of the phase IV RESOLUTION trial were presented at... |
| 22.05.2025 | Lundbeck successfully places a EUR 500 million Eurobond | Lundbeck successfully places a EUR 500 million Eurobond
Thu, May 22, 2025 17:31 CET Report this content
Valby, Denmark, 22 May 2025 - H. Lundbeck A/S (Lundbeck) has successfully placed an aggregate principal amount of EUR 500 million senior... |
| 09.05.2025 | Winter Wellness: A Guide for Seniors to Thrive in Cold Weather | Winter is a double-edged sword. It brings beauty and wonder, but it also poses challenges, especially for seniors. As the temperature drops, the risks rise. Icy sidewalks become treacherous, and the cold can seep into homes, leading to heal... |
| 08.05.2025 | Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston | Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston
Thu, May 08, 2025 08:00 CET Report this content
H. Lundbeck A/S (Lundbeck) will present ... |
| 06.05.2025 | Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer | Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer
Tue, May 06, 2025 08:00 CET Report this content
H. Lundbeck A/S is pleased to announce its agreement... |
| 05.04.2025 | Lundbeck's Bold Moves in Migraine and Epilepsy Treatments: A New Dawn for Patients | In the world of pharmaceuticals, innovation is the lifeblood. Lundbeck, a biopharmaceutical company, is making waves with its latest developments in migraine and epilepsy treatments. The company is expanding its research horizons, aiming to... |
| 04.04.2025 | Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting | Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting
Fri, Apr 04, 2025 09:00 CET Report this content
H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension ... |
| 31.03.2025 | Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention | Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention
Mon, Mar 31, 2025 11:00 CET Report this content PROCEED is an adaptive Phase IIb ... |
| 28.03.2025 | The Future of Health and Food: Innovations in Pharmaceuticals and Precision Fermentation | In the fast-paced world of health and nutrition, two recent developments stand out. One is a groundbreaking partnership in pharmaceuticals, while the other is a leap forward in food technology. Both aim to tackle pressing global issues: chr... |
| 27.03.2025 | Melt&Marble Strengthens Leadership to Scale Precision-Fermented Fat Production | Melt&Marble, a company specializing in precision-fermented fats, has announced two significant additions to its leadership team as it prepares for large-scale commercial production.
Tue Hodal, a veteran of industrial biotech and pharma,... |
| 26.03.2025 | Lundbeck held its Annual General Meeting on 26 March 2025 at the company’s registered office | Lundbeck held its Annual General Meeting on 26 March 2025 at the company’s registered office
Wed, Mar 26, 2025 12:28 CET Report this content
H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted an... |
| 13.03.2025 | Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older | Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Thu, Mar 13, 2025 09:00 CET Report this content
Brexpiprazole’s indication for the treatment of schizophrenia... |
| 12.03.2025 | The Future of Neurorehabilitation: Innovations and Breakthroughs | In the world of healthcare, innovation is the lifeblood that keeps the industry thriving. Recently, two remarkable developments have emerged in the realm of neurorehabilitation. One is a groundbreaking software startup that harnesses augmen... |
| 10.03.2025 | Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan | VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Mu... |
| 10.03.2025 | Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan | Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
Mon, Mar 10, 2025 09:01 CET Report this content
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designati... |
| 25.02.2025 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 25, 2025 10:00 CET Report this content Notice of Annual General Meeting
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: Wednesday, 26 March 2025 at 10:00... |
| 21.02.2025 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Fri, Feb 21, 2025 13:27 CET Report this content
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by ... |
| 20.02.2025 | The Rise of Healthcare Marketing: A New Era of Innovation and Strategy | The healthcare marketing landscape is evolving. Agencies are no longer just service providers; they are strategic partners in the healthcare ecosystem. Two recent developments highlight this shift: Moon Rabbit's impressive growth and Strate... |
| 19.02.2025 | Moon Rabbit Wraps 2024 with Key Executive Hires, New NYC Headquarters, Major Client Wins | Healthcare agency also won Fierce Pharma's 'Best New Brand Launch' award, opened London office, instituted workplace enhancements for expanding team
NEW YORK, Feb. 19, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and m... |
| 12.02.2025 | Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA | Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
Wed, Feb 12, 2025 09:00 CET Report this content
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug,... |